Discovery About Biofilm Could Benefit Cystic Fibrosis Patients
New drug awarded up to $8.9 million
Because of Anderson’s discovery, new medications are being developed to fight bacteria causing CF. Antabio SAS is a French biopharmaceutical company devoted to developing new antibacterial treatments for CF. They have received up to $8.9 million dollars of funding from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the world’s largest public-private partnership devoted to antibacterial research and development. Antabio SAS gets $2.8 million up front for research and will receive up to the full $8.9 million throughout their studies.
